Autres langues RemeGen Co., Ltd.

Actions

9995

CNE1000048G6

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:13 03/07/2024			Varia. 5j.	Varia. 1 janv.
22,6 ^HKD	0,00%		-14,72%	-39,65%

14/06	L'essai clinique de phase 3 de RemeGen sur le cancer du sein atteint son objectif principal ; les actions augmentent de 3 %.	MT
13/06	RemeGen Co. annonce que l'étude clinique de phase III du Disitamab Vedotin pour injection dans le traitement du cancer du sein avancé HER2-positif avec métastases hépatiques a atteint le critère d'évaluation principal de l'étude.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

RemeGen Phase Three Breast Cancer Clinical Trial Meets Primary Endpoint; Shares Rise 3%	14/06
RemeGen Co., Ltd. Announces Phase III Clinical Study of Disitamab Vedotin for Injection for the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis Met Primary Study Endpoint	13/06
Grange Resources Appoints CEO	28/05
Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05
RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04
Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication	04/04
Remegen Co., Ltd. Announces FDA Grants Telitacicept Fast Track designation for Treatment of pSS	02/04
Remegen Plans A-Share Private Placement to Fund New Drug Development Project	29/03
RemeGen Co., Ltd. announced that it expects to receive CNY 2.549999941 billion in funding	29/03
RemeGen Co., Ltd.(XSSC:688331) added to FTSE All-World Index	18/03
RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin for Cervical Cancer At ESGO 2024	11/03
RemeGen's 2023 Net Loss Widens; Revenue Jumps 40%	26/02
RemeGen Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
RemeGen's Loss to Widen in 2023	31/01
RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023	30/01
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	24/01
RemeGen Buys Back HK$12 Million Worth of Hong Kong Shares	23/01
RemeGen Denies Rumors of Tight Cash Flow, Funding Hurdles	17/01
La población china vuelve a descender, con la tasa de natalidad más baja en los registros	17/01
RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients	12/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues RemeGen Co., Ltd.

Actions

9995

CNE1000048G6

Autres langues

Filtres